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Introduction:We report the long term and overall results of a triplet
induction chemotherapy regimen followed by standard radiotherapy
in patients with locally advanced inoperable stage III non-small cell
lung cancer.
Methods: Three cycles of paclitaxel, carboplatin, and gemcitabine
were administered every 3 weeks before standard fractionated con-
solidation radiotherapy starting at least 4 weeks after the last
chemotherapy administration. Toxicity and antitumor response was
assessed in detail as well as the progression free and overall survival.
Results: Sixty-four patients (25 stage IIIA and 39 stage IIIB)
received a total of 179 cycles of chemotherapy. Fifty-six received
the planned three cycles. Full-dose radiotherapy was administered in
47 patients (73%), a reduced dose in 11 (17%) and none in six
(10%). A 55% objective response rate (OR) (one complete and 34
partial responses) was observed after induction chemotherapy. After
completing the whole treatment including radiotherapy, the OR was
40 of 47 evaluable patients (85%). Median time to progression was
10.9 month and median overall survival was 17.2 month, with a
significant difference between stage IIIA and stage IIIB patients
(23.4 versus 10.5 month; p  0.011). The strongest predictor for a
favorable long-term outcome was a metabolic complete response
after chemotherapy.
Conclusion: Induction chemotherapy with the paclitaxel, carbopla-
tin, and gemcitabine regimen preceding radiotherapy in patients with
locally advanced inoperable stage III non-small cell lung cancer was
feasible and active. Radiotherapy could be administered at a full
dose in the majority of patients with acceptable toxicity. Long-term
survival results of this sequential chemoradiotherapy regimen ap-
pear similar to those of concurrent treatment. Patients not achieving
a metabolic complete response after induction chemotherapy should
be the focus of studies aiming at improved local control.
Key Words: NSCLC, Locally advanced (stage III), Induction
Chemotherapy, Radiotherapy.
(J Thorac Oncol. 2009;4: 728–735)
Non-small cell lung cancer (NSCLC) frequently presents in a
locally advanced inoperable stage III and bears a poor prog-
nosis with a global 1 and 5-year survival of 32 to 64% and 3
to 23% for stages IIIA and IIIB, respectively.1 Radiotherapy
has been the cornerstone of treatment of this presentation of
lung cancer. Sixty gray of irradiation delivered continuously
by daily fractions in 6 weeks is presently considered as
minimal standard of local therapy.2 Current research focuses
on optimization of radiotherapy delivery taking into account
assessment of tumor motion, precision of tumor volume
definition, and better understanding of radiation dose distri-
bution/delivery (e.g., 3D conformal radiotherapy and inten-
sity modulated radiotherapy). Local relapse and distant fail-
ure leading eventually to death in a large number of patients
are nevertheless highly indicative of suboptimal treatment.2
The optimal treatment strategy for these patients remains to
be defined. The American Society of Clinical Oncology
guidelines recommend combined modality treatment with
platinum-based chemotherapy and definitive thoracic radia-
tion particularly for patients with good performance status.2
Randomized studies3–6 and a recent meta-analysis7 suggest
that concurrent chemoradiotherapy leads to a superior out-
come compared with sequential treatment at the expense of
increased local toxicity. Whereas platinum-based doublets
remain the standard regimen, the choice, and addition of a
third complementary agent is the subject of investigation. In
the setting of stage IIIB–IV NSCLC, no clear or only mar-
ginal differences exist between platinum-based doublets and
triplets.8 However, addition of gemcitabine to a platinum
doublet was shown marginally superior in a meta-analysis
compared with a platinum doublet including a first or second
generation drug without gemcitabine.9 Furthermore, the ad-
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dition of gemcitabine to the carboplatinum-paclitaxel doublet
was demonstrated to be safe and to result in a significantly
superior treatment outcome in a phase II to III study in
advanced NSCLC compared with carboplatinum-paclitaxel
alone.10 In operable NSCLC, the cis- or carboplatin-contain-
ing triplet combinations used as induction chemotherapy
(including paclitaxel and gemcitabine) before surgery were
shown superior to doublet combinations in individual non-
randomized studies.11
The assumption of potentially increased antitumor
efficacy of the triplet and its safety constituted the ratio-
nale for combining the paclitaxel, carboplatin, and gem-
citabine (PACCAGE) regimen with radiotherapy in a se-
quential program delivering the chemotherapy first followed
by consolidation radiotherapy in patients with inoperable
NSCLC. Phase II results (efficacy and toxicity) of the che-
motherapy part (PACCAGE) were recently published on 48
patients.12 Here, we report the final analysis of the total
cohort of 64 patients included in the study, their response and
long-term outcome.
PATIENTS AND METHODS
Patients from a single institution older than 18 years
with histologically or cytologically confirmed NSCLC, clin-
ical stage IIIA or stage IIIB (without malignant pleural
effusion), Karnofsky Performance Score of 80 to 100, who
were not candidates for surgery, did not undergo previous
radiotherapy or chemotherapy or did not suffer from a pre-
vious cancer (except for basocellular epithelioma of the skin
or in situ cancer of the cervix assumed to be cured with a
follow-up of more than 5 years), and signed informed consent
were enrolled from January 4, 2001 till January 10, 2005.
Patients were staged clinically and those with enlarged medias-
tinal lymph nodes visualized on computerised axial tomography
(CT) scan and with positive spots on 18fluoro-deoxy-glucose
(18FDG)—positron emission tomography (PET) scan were
considered inoperable according to the institutional surgical
guidelines and eligible for the study. Those who underwent a
thoracotomy after a negative mediastinoscopy and were
judged inoperable were also eligible for the study. Ineligibil-
ity included patients with T4 tumors invading the vertebral
body or supraclavicular lymph nodes, presence of atelectasis
of the whole lung, and a tumor of the superior sulcus.
Standard eligibility criteria for chemotherapy included ade-
quate blood chemistry, normal bone marrow, hepatic and
renal function, and absence of severe pulmonary or cardio-
vascular disease. Eligibility for induction chemotherapy fol-
lowed by radiotherapy was assessed during a multidisci-
plinary consultation in the presence of a medical oncologist
and a radiotherapist.
Assessment Procedures
Pretreatment evaluation included patient history, phys-
ical examination, performance status, standard chest x-ray,
complete blood chemistry and blood count, CT scan of the
chest and abdomen, bone scintigraphy, fiberoptic bronchos-
copy plus biopsy, 18FDG-PET-scan, and any other clinical or
radiologic procedure deemed necessary to rule out metastatic
disease. Mediastinoscopy was performed only in otherwise
surgical candidates. These examinations were performed
within 4 weeks of the first administration of chemotherapy. A
complete blood count and clinical examination was per-
formed weekly (days 1, 8, and 15 of a 3-week cycle) during
chemotherapy. Complete blood chemistry was performed on
day 1 of each new cycle. A complete clinical and radiologic
reevaluation using the same imaging techniques as before
chemotherapy was performed before radiotherapy (within
3–4 weeks after the last chemotherapy administration in
cycle 3) and 1 to 2 month after completion of radiotherapy.
The possibility to repeat the examinations earlier was an
option for patients with a suspicion of progressive disease
before scheduled reevaluation. During follow-up, a clinical
examination, a hematological, and biochemical blood evalu-
ation and a CT scan of the thorax was mandatory every 3, 4,
and 6 months in the first 2 years in years 3 and 4 and year 5
and beyond, respectively. The clinical response to induction
chemotherapy and to radiotherapy was assessed using CT
scan according to the World Health Organisation criteria.13
Objective response rate (OR) was defined as the sum of the
complete plus partial response (PR) rate. In a subgroup of
patients, 18FDG-PET scan was added after induction chemo-
therapy in parallel with CT scan but not always repeated after
radiotherapy. Response on 18FDG-PET was defined accord-
ing to the completeness of the resolution of enhanced 18FDG
uptake in the tumor as detailed previously.14 All patients
accrued into the study were included in the final analysis.
Treatment Delivery
Chemotherapy
On day 1 of each chemotherapy cycle, paclitaxel (175
mg/m2 by 3-hour infusion on day 1) preceded the adminis-
tration of carboplatin (AUC 5 mg/ml. min by IV bolus) and
gemcitabine (1000 mg/m2 by IV bolus). On day 8, gemcit-
abine (1000 mg/m2 by IV bolus) was repeated. On day 1 of
each cycle premedication consisted of ondansetron (8 mg IV
bolus), dexamethasone (20 mg IV bolus), promethasine (50
mg s.c.), and ranitidine (300 mg IV bolus), all administered
30 minutes before paclitaxel. Oral ondansetron was adminis-
tered if necessary after day 1. On day 8, 50 mg of alizapride
by IV bolus was given 30 minutes before gemcitabine and
continued orally if necessary afterward.
Dose Reductions of Chemotherapy. Doses were reduced ac-
cording to hematological and nonhematological NCI-CTC ver-
sion 2.0 toxicity criteria.15 No dose reescalation was allowed if
a dose had to be reduced previously. The details of the guide-
lines and procedures of dose reductions on days 1 and 8 of each
cycle according to hematological and nonhematological toxicity
were published before.12
Radiotherapy
Radiotherapy was initiated at least 4 weeks after com-
pletion and recovery from induction chemotherapy toxicity.
For radiotherapy planning purposes, patients underwent
“slow” CT (Somatom, Siemens, Erlangen, Germany) in
supine position. Image sets were constructed, with and with-
out iodine contrast enhancement (100 mL of Telebrix-35tr).
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Delineation and dose computation were performed on the
GRATIS planning system implemented on a Unix work
station (Ultra-2, Sunsparc). Whenever available, images of
the diagnostic 18FDG-PET were used for planning purposes.
They were imported in the delineation console to allow for
proper fusion using Syntegra in stead of coregistration. Final
delineation was performed on the “a blanc” CT series. Using
W  1600 and L 300 for the parenchyma, and W  400
and L  800 for the mediastinum. The contrast series was
useful in adjusting the delineation, but it could not be used for
dose computation. The 18FDG-PET data were used to distin-
guish tumor from atelectasis or to locate mediastinal lymph
node involvement when not visible on CT. The following
target volumes were defined: gross tumor volume (GTV)
primary, GTV nodes (all lymph nodes with a short axis of1
cm, lymph nodes 1 cm when clustered), clinical target
volume (CTV) primary (a 5-mm three-dimensional expansion
around the GTV primary in the parenchyma or mediastinum,
with exclusion of mediastinal vessels, bone, heart or esoph-
agus, unless diagnostic imaging revealed a T4-stage due to
invasion in the previously mentioned structures), and CTV
nodes (all lymph node regions in which GTV nodes were
defined, based on either CT imaging, 18FDG-PET, histologic
or cytologic evidence or combination of these). Delineation
of the entire attained lymph node region according to the
Naruke classification was performed to obtain the CTV
nodes, however, without elective nodal irradiation. Planning
tumor volume (PTV) margins were 5 or 8 mm for primary
tumors in either upper or middle/lower lobe location, respec-
tively. PTV expansion on CTV nodes was 3 mm. Three-
dimensional, coplanar, conformal beam setup was used for
planning purposes using up to six beam incidences. The plan
objective was to deliver 66 Gy in 2 Gy fractions to the entire
PTV according to ICRU guidelines, without violation to the
normal dose constraints. Dose constraints for organs at risk
were set as follows: maximal dose to the spinal cord of 53 Gy
in 30 fractions, the volume receiving 20 Gy of the entire lung
minus GTV (V20) below 30% and the mean lung dose below
17 Gy, less than one third of the esophagus could receive 66
Gy, and less than half 35 Gy. In case of conflict between PTV
coverage and dose to the spinal cord or lungs, priority was
given to the organ at risk and dose was lowered to 60 Gy.
Patients showing evidence of progressive disease at any site
were excluded from high dose radiotherapy and were treated
with palliative intent when indicated. Dose schedules varied
depending on the presence of extra thoracic disease, the
tumor volume, and the general condition of the patient.
Acute and late lung toxicity was scored using the
RTOG/EORTC morbidity scoring classification. Radiologic
changes were evaluated by two physicians independently on
repeated CT scans. Changes in pulmonary function tests (PFTs)
were categorized using the SOMA/LENT scale, primarily eval-
uating the 1 second forced expiratory volume (FEV1) and lung
diffusion capacity for carbon monoxide (DLCO).16
Supportive Treatments
Growth factors (filgrastim, recombinant human eryth-
ropoietin), transfusions (red blood cells, platelets), antibiot-
ics, and other supportive drugs or measures during induction
chemotherapy were used when necessary. Dose delays and
reductions were recommended rather than the use of second-
ary prophylaxis for neutropenia with filgrastim.
Statistical Analysis
The study was initially conceived as a phase II study of
triplet induction chemotherapy (before consolidation radio-
therapy) in stage III unresectable NSCLC. To reject an
acceptable OR of 45%, 31 eligible patients had to be
accrued in the study.17 After the demonstration of an OR of
45% and the feasibility to deliver full-dose radiotherapy in
the first cohort of patients, an amendment was approved to
include a nonspecified additional number of patients. All
analyses were performed according to the intention-to-treat
(ITT) principle.
Confidence limits (95% CI) of response rate were
estimated according to Simon.18 Time to progression and
time to survival were defined as the period from the first day
of treatment to the date of first evidence of disease progres-
sion and/or death or to loss of follow-up, respectively. Sur-
vival estimates were generated using the method of Kaplan
and Meier.19 To study the potential influence of major base-
line characteristics (stage of disease, age, sex, histology, and
PS) on survival, a uni- and multivariate analysis according to
the Cox logistic regression model was performed.20
RESULTS
Patient Characteristics
A total of 64 patients were enrolled in this study, and
disease characteristics are detailed in Table 1. Twenty pa-
tients presented with T3 and 25 with T4 tumors. The patients
with T16 and T213 tumors were classified in the stage IIIA or
stage IIIB category based on the mediastinal nodal status (N2
or N3). Only three of the patients included were inoperable
after exploratory thoracotomy. In the remaining 61 patients,
inoperability was decided upon clinical staging. A compara-
tive analysis of outcome with 18FDG-PET and CT response
before and after induction chemotherapy was possible in 31
patients.14 Assessment of the overall treatment response (che-
motherapy and radiotherapy) was possible in 47 patients.
Treatment Delivery
Induction Chemotherapy
All but one patient received at least one cycle of
chemotherapy. One female patient developed a grade 3 ana-
TABLE 1. Patient Characteristics
Number 64
Median age, yr (range) 66 (39–78)
Male/female (%) 51/13 (80–20)
Stage IIIA/IIIB (%) 25/39 (39–61)
Karnofsky Performance Score 100-90-80 (%) 11/42/11 (17/66/17)
Histology (%)
Squamous cell cancer 29 (45)
Adenocarcinoma 14 (22)
Large cell carcinoma 10 (16)
Undefined 11 (17)
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phylactic reaction 10 minutes after the start of the first
paclitaxel administration despite adequate premedication and
was not rechallenged with PACCAGE. Fifty-six patients
have received at least day 1 of the planned three cycles. Eight
patients did not receive the planned three cycles: three pa-
tients with early progressive disease (two in cycle 1 and one
in cycle 2) of whom one with early death; two patients with
early tumor-related events (lethal pulmonary infection in one
and massive hemoptysis in one) in the absence of any toxicity
in cycles 1 and 2, respectively, and three patients with
treatment related toxicity (one anaphylactic reaction cfr supra
and two with grade 3 gastro-enteritis during cycles 1 and 2,
respectively). Each new cycle was started on time and dose
reductions on day 1 of the cycles were applied in 20
(10.4%), 21 (10.9%), and 22 (11.5%) of the administra-
tions of paclitaxel, carboplatin and gemcitabine, respec-
tively. Administration of gemcitabine on day 8 of the
cycles was omitted and reduced in dose, 21 (10.9%) and 44
times (22.9%), respectively.
The cumulative percentages of the planned doses for
the three drugs on day 1 of each cycle in cycles 1 to 3 were
98, 89, and 82% and on day 8 for gemcitabine alone 90, 70,
and 62%.
The hematological and nonhematological toxicity and
the incidence/reasons for dose reductions and omissions in
the total population are in line with our previous report12 and
are detailed on Table 2.
With the inclusion of 14 supplementary patients, no
unexpected additional toxicities were observed. Approxi-
mately 70% of the patients presented grade 3 or grade 4
neutropenia mainly occurring on day 15 of the cycles. Grade
3 and grade 4 leucopenia, thrombocytopenia, and anemia
were less frequent. No significant clinical manifestations
emerging from myelosuppression such as fever, infection, or
major bleeding were observed. In two patients dying during
induction chemotherapy, one from pneumonia and another
from massive hemoptysis, neither grade 3/4 neutropenia nor
thrombocytopenia was identified. Of 56 patients receiving the
intended three cycles of induction chemotherapy, 26 were
able to receive the day 1 and day 8 administration without
delay, dose reduction, or supportive measures. In the remain-
ing 30 patients, hematological support including recombinant
erythropoietin was needed in 25, either alone (17 patients),
simultaneously with granulocyte colony stimulating factor
(G-CSF) (one patient), in combination with red blood cell
transfusion (RBCT) (four patients), a RBCT plus G-CSF (one
patient) or a RBCT plus a platelet transfusion (two patients).
In additional two and three patients, G-CSF or a RBCT alone
were necessary, respectively.
Salvage Systemic Therapy
On completion of consolidation radiotherapy, only 13
of 50 relapsing patients received salvage second or further-
line systemic treatment. This consisted mainly of single agent
therapy with vinorelbine, docetaxel, gemcitabine, pem-
etrexed, or a tyrosine kinase inhibitor. Four patients received
a tyrosine kinase inhibitor as only salvage therapy. With
salvage chemotherapy only three disease stabilizations with
short duration were observed (2 as the second line and 1 as
the third-line chemotherapy). The number of patients with
stage IIIA or stage IIIB receiving no salvage systemic therapy
was identical: 13 of 19 (68%) and 24/35 (69%) in stages IIIA
and IIIB, respectively.
Radiotherapy
Radiotherapy was initiated 41 days (median value)
after completion of induction chemotherapy. Delivery of
full-dose radiotherapy was achieved within a median num-
ber of 45 days.
A full radiotherapy “dose equivalent” of 66 Gy on the
primary tumor and lymph nodes was delivered in 47 patients
(73%). The dose of radiotherapy was reduced to 45 Gy in
11 patients (17%). In five of them, this was because of
development of metastases and in three because of local
progression during radiotherapy. In additional three patients,
the dose was reduced for technical reasons (tumor volume).
No radiotherapy was delivered in six patients (10%), in five
because of demise before radiotherapy could be initiated: one
patient died during the first cycle of chemotherapy due to PD,
two patients died during chemotherapy due to tumor-related
events in the absence of progressive disease and two patients
died between chemo- and radiotherapy. One patient under-
went surgery after induction chemotherapy and appeared to
be a pathologic complete responder.
Toxicity of Radiotherapy
Acute
One patient died within 4 weeks after the end of
radiotherapy with the acute respiratory distress syndrome.
Autopsy revealed a combined effect of radiation pneumo-
nitis, tumor progression, and infection. In all patients, a
grade 3 acute esophagitis lasting for 2 to 4 weeks was
observed.
TABLE 2. Toxicity of Chemotherapy
Toxicity Grade 3 (%) Grade 4 (%)
Hematological
Leucopenia 20 (31.3) 2 (3.1)
Neutropenia 22 (34.4) 23 (35.9)
Thrombocytopenia 14 (21.9) 6 (9.4)
Anemia 2 (3.1) 1 (1.6)
Infection 2 (3.1) 1 (1.6)
Nonhematological
Nausea/vomiting 4 (6.2) 0
Arthralgia/myalgia 5 (7.8) 0
Diarrhea 3 (4.7) 0
Polyneuropathy 1 (1.6) 0
Rash 2 (3.1) 0
Anaphylaxis 1 (1.6) 0
Fatigue 1 (1.6) 0
Nonthrombopenic hemoptysis 0 1 (1.6)
Values are presented as n (%); n  64.
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Late
No grade 3 or more late esophageal toxicity could be
reported. Late lung toxicity measured in changes in PFTs was
acceptable. In more than half of the patients the change in
PFTs when compared with the baseline value was less than
25%. Only 7% of patients experienced a decline of more
than 50% (Soma-Lent criteria). Lung toxicity based on the
RTOG-EORTC criteria showed radiologic changes in 80%
of patients with a patchy dense pneumonitis in six patients.
Adding the clinical data, the incidence of grade 3 radiation
pneumonitis rose to 18%. Overall, late lung toxicity included
a grade  grade 2 SOMA-LENT and a grade  grade 3
RTOG/EORTC toxicity in 44% and 18% of the patients,
respectively (Figures 1A, B).
Response
Induction Chemotherapy
The response rate of the ITT population was 55%
(Table 3). In the category “Not Evaluable” (NE) for response,
five patients did not receive the planned three cycles because
of toxicity (three patients) or early death (two patients). Only
four patients developed progressive disease under chemo-
therapy and they received one (two patients), two (one
patient), or three cycles (one patient) of chemotherapy.
The single patient (stage IIIB) who underwent “curative”
surgery in stead of radiotherapy after completion of induc-
tion chemotherapy is reported under PR.
Overall Treatment Effect
Of the 64 patients constituting the ITT study population
only 47 patients (40 received a full-dose radiotherapy and
seven a reduced dose) had comparative CT scans before and
1 to 2 months after completion of radiotherapy. The average
calculated remaining tumor surface in these 47 patients after
induction chemotherapy was 41% (range 6–122%). After the
consolidation radiotherapy, this was further reduced to a
calculated surface of 29% or a total reduction of 71%. This
finding suggested a larger tumor “shrinkage” with chemo-
therapy than with consolidation radiotherapy (59% versus
29% relative reduction, respectively). Respectively, 30
and 17 of these 47 patients achieved a PR (64%) and minor
response or stable disease (36%) after induction chemo-
therapy. All of the 30 patients with a PR after induction
chemotherapy remained in PR after consolidation radio-
therapy, whereas 10 of 17 patients with minor response or
stable disease after induction chemotherapy were con-
verted into PR.
Survival Parameters
Time to Progression
With a median follow-up of patients alive of 59.1
month (range 39.2–82.4 month), the median time to progres-
sion of the ITT population was 10.9 month (95% CI: 7.9–
13.5 month) (Figure 2A). Stage IIIA patients achieved a
significantly longer time to progression compared with stage
IIIB patients (15 versus 8.7 month; p  0.049).
Eight of the 64 patients included are alive without
clinical or radiologic evidence of relapse at time of the most
recent evaluation (December 15, 2008). Fifty-six patients
have died of whom six with no relation to tumor relapse and
four with unknown reasons. In 46 patients, the pattern of
initial relapse could be documented: local relapse only in 18,
metastatic only in 10, and a combination of local relapse plus
metastases in 18. In nine patients initial relapse was in the
brain, in six as the only site. No specific histologic subtype
predisposing for brain metastasis was found in this series.
Survival
The median survival of the ITT population was 17.2
month (95% CI: 12.8–22.6 month) with a significant differ-
FIGURE 1. A, B, Late lung toxicity of radiotherapy; RTOG/
EORTC (B) and SOMA-LENT (A) scale.
TABLE 3. Radiological Responce After Induction
Chemotherapy
CR PR SD PD NEa
Stage IIIA (n  25) 0 18 5 1 1
72% (CI 54–90%)
Stage IIIB (n  39) 1 16 15 3 4
46% (CI 28–59%)b
All (n  64) 1 34 20 4 5
55% (CI 42–67%)
a Not evaluable: early death: 2 (pneumonia cycle 1, hemoptisis cycle 2); gastroin-
testinal toxicity GR 3: 2 (cycle 1 and 2); anaphylaxis to P GR 3: 1 (cycle 1).
b P  (Fisher’s exact test).
CR, complete response; PR, partial response; SD, stable diease; NE, not evaluable;
PD, progressive disease; CI, confidence interval.
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ence between stage IIIA and stage IIIB patients (23.4 versus
10.5 month; p  0.011) (Figure 2B). An update of the
survival data in patients evaluated through 18FDG-PET
demonstrated that patients with a metabolic complete re-
sponse (mCR) lived significantly longer than those without
mCR (49 versus 14 month p  0.005), which corroborated
the previously published results.14 The number of patients
that underwent a repeat assessment with 18FDG-PET after ra-
diotherapy was too small to allow any further analysis on the
potential impact of the consolidation radiotherapy. The % 5-year
survival was 12.5% overall, favoring stage IIIA patients (17.5%
and 6.4% in stages IIIA and IIIB, respectively).
In the subset of 47 patients in whom a CT scan was
available before induction chemotherapy and after consolidation
radiotherapy, a reduction of 80% of the initial tumor surface
on CT was predictive for a longer median time to progression
(11 versus 18.6 month; p 0.0117) but only a trend for survival
was observed (15.7 versus 31.1 month; p  0.111).
DISCUSSION
We have demonstrated that the use of induction che-
motherapy with three cycles of PACCAGE before consoli-
dation radiotherapy is safe and active in patients with stage III
NSCLC. These results are in line with earlier data using the
same chemotherapy in stages IIIB to IV NSCLC.21–23 Ex-
panding the number of patients from 48 in our previous report
to the total of 64 included in the trial did not alter the toxicity
nor activity results significantly. The OR obtained in the
present report was 55%, slightly less than in the previous one
(62.5%).12 Of notice is the superior response in stage IIIA
(72%) versus IIIB (46%) patients indicating a higher activity
of chemotherapy with lower tumor burden. In the study by
Abratt et al. and Giannotti et al.,11,24 81.5% and 72.7% OR
was obtained after three cycles of an identical regimen before
surgery in 29 stage IIIA (out of a total of 44) and 52 bulky
stage IIIAN2 patients, respectively. Although OR was high in
these studies, a pathologic complete responder was rather
exceptional (five and four patients, respectively). The fact
that the antitumor activity of the PACCAGE regimen corre-
lates with stage and/or volume of disease is also illustrated by
the comparison of the three other studies.21–23 In the first
study that included 90% of stage IV patients, the overall OR
was 26%.21 In the second study 73% of the patients were
stage IV and the OR increased to 44%.23 Finally in the third
study, 28 of 41 patients included were in stage III and the OR
in these patients was 68%.22
Mainly nonhematological toxicity and early tumor-
related events was the reason for early termination of che-
motherapy in eight patients in our study. Nevertheless, he-
matological toxicity may have been underestimated in the
present study because of the mandatory dose reductions and
as a consequence of the potential underreporting of hemato-
logical toxicity on day 15 during cycles 2 and 3 (not all
patients had blood counts done on day 15 of cycles 2 and 3).
Fifty-six patients (91%) were, however, able to complete the
intended three cycles, some at a reduced dose.
We were also able to show that standard full-dose
radiotherapy could be delivered in time in 73% of the patients
with acceptable toxicity. The reasons for not being able to
deliver the full dose were in the majority of cases not
radiotherapy, but rather tumor—or patient related. Neverthe-
less, apart from the well known and transient esophageal
toxicity, lethal acute pulmonary toxicity in combination
with infection and local tumor progression was observed in
one patient only. The late pulmonary toxicity grade 3 was
similarly acceptable and comparable with other sequential
chemoradiation regimens.25 Although no direct compari-
son is possible with concurrent chemoradiotherapy, acute
and late toxicity seems to favor our sequential approach.7
The median survival of 17.2 months obtained overlaps
with the median survival reported in the four randomized
studies of sequential versus concomitant chemoradiotherapy
(16.5 month, range 16.3–17.0 month).3–6 In our stage IIIA
patients, a survival of 17.5% at 5 year is observed. This seems
similar to the results of the concomitant chemoradiotherapy
rather than the sequential arms in the randomized studies
(16%, 21%, and 19% 5-year survival for Furuse et al.,
Fournel et al., and Zatloukal et al., respectively).3,5,6 Thirty-
nine percentage of our patients presented with stage IIIA
quite comparable with 44%, 33%, and 15% of patients with
stage IIIA enrolled in the concurrent arms of the randomized
studies, respectively.3,5,6 The favorable results obtained in our
stage IIIA population could also be explained by the potential
selection bias of more “low volume” disease in our stage IIIA
cohort. No clear explanation is available for the poor
median survival of 10.5 month in the present stage IIIB
patient cohort compared with a previously published 10.8
months with an analogous chemotherapy regimen in ap-
FIGURE 2. A, B, time to progression (A) and overall survival
(B). Full line represents the total population, dotted line repre-
sents stage IIIA dashed line represents and stage IIIB patients.
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parently far more advanced “wet” stage IIIB and IV
disease.10 Indirect proof of a selection of a poor prognostic
group of stage IIIB patients in the present study may be
suggested by the large number of patients failing to com-
plete the full treatment program including the induction
chemotherapy and the consolidation radiotherapy part in
stage IIIB (23 of 39) (data not shown).
Treatment failure in locally advanced NSCLC includes
local and metastatic relapse in most of patients.2 In the
present study around 50% or more of the patients with
long-term follow-up presented with local and metastatic re-
lapse. Improved radiotherapy and better systemic treatments
need therefore to be developed. Our observations14 and
those of others26 about the predictive power of a local
mCR by 18FDG-PET and a long-term survival after induc-
tion treatment is suggestive for using this tool to guide the
consolidation radiotherapy. Especially those patients, not
achieving a mCR after induction chemotherapy are poten-
tially at high risk for first local relapse and should be
offered higher radiotherapy doses (e.g., via intensity-mod-
ulated Radiotherapy) or be the subject of research aimed at
improving local control. Furthermore, better systemic
treatments are needed to achieve better local and systemic
effects.
The high incidence of first relapse in the brain, with six
patients of 64 developing them as the only site in our study
should receive special attention. A baseline magnetic reso-
nance imaging scan of the brain may therefore be useful
before the start of induction chemotherapy and before con-
solidation radiotherapy in the absence of any clinical central
nervous system symptomatology. This may avoid the unnec-
essary morbidity of chemo- and radiotherapy administered
with curative intent. These data support prophylactic cranial
irradiation (PCI) in selected patients such as adenocarcinoma,
a minority in our population, that have a high propensity for
the development of brain metastases and more specifically
those patients that have a high probability of long-term
survival predicted by a mCR. One small randomized study
demonstrated a significant reduction in the incidence of
brain metastasis in patients with operable stage IIIA
NSCLC undergoing PCI added to induction chemotherapy
and concomitant chemoradiotherapy followed by surgery
versus no PCI. The neurocognitive functioning was pre-
served in that study.27
In conclusion, we have shown that induction chemo-
therapy adding gemcitabine to the doublet consisting of
carboplatinum and paclitaxel followed by standard consoli-
dation radiotherapy is active and feasible in stage III inoper-
able NSCLC. Whether the novel triplet is superior to the
currently used doublets as induction chemotherapy (in
terms of clinical activity, toxicity, outcome, and econom-
ical cost) or achieves long-term results compared with
concomitant chemoradiotherapy should be evaluated in a
randomized trial.
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